Bio-Rad

Executives provided updates on their companies at the 35th Annual JP Morgan Healthcare Conference in San Francisco.

The Norwegian microbiome-focused clinical diagnostics company has ceded commercialization rights in certain undisclosed territories to Bio-Rad as part of the deal.

The firm reported revenues of $508.7 million, thanks largely to an 18 percent increase in sales from the company's life science segment. 

The deal gives Bio-Rad licensing rights to a PCR-based platform and an assay that improves diagnostic sensitivity and efficacy across four dengue serotypes.

Researchers are using Bio-Rad's droplet digital PCR technology to validate seven ctDNA biomarkers that may predict melanoma recurrence.

The firm's life science sales were driven by increased sales for its Droplet Digital PCR and process chromatography products.

The firm's multi-analyte quality controls for nucleic acid tests are designed to help large and small labs mitigate quality challenges. 

The Olivia Newton-John Cancer Research Institute in Melbourne received accreditation in Australia to perform mutation testing using Bio-Rad's droplet digital PCR.

Life Science segment sales grew 10 percent on a currency-neutral basis, benefiting in part from increased sales of Droplet Digital PCR products.

Bio-Rad reported $570.6 million in revenues in Q4, a 5 percent drop year over year but a 3 percent increase on a currency-neutral basis.

Pages

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.